fms-Like Tyrosine Kinase 3

A receptor tyrosine kinase that is involved in HEMATOPOIESIS. It is closely related to FMS PROTO-ONCOGENE PROTEIN and is commonly mutated in acute MYELOID LEUKEMIA.

Also Known As:

CD135 Antigen; Fetal Liver Kinase-2; Fetal Liver Kinase-3; Stem Cell Tyrosine Kinase 1; Antigen, CD135; Fetal Liver Kinase 2; Fetal Liver Kinase 3; fms Like Tyrosine Kinase 3; Antigens, CD135; CD135 Antigens

Networked: 490 relevant articles (22 outcomes, 36 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Levis, Mark J: 16 articles (01/2022 - 11/2006)
2.	Ravandi, Farhad: 15 articles (01/2022 - 01/2011)
3.	Small, Donald: 14 articles (11/2021 - 03/2004)
4.	Cortes, Jorge: 11 articles (01/2021 - 02/2008)
5.	Levis, Mark: 10 articles (12/2020 - 03/2004)
6.	Baer, Maria R: 9 articles (01/2022 - 01/2013)
7.	Borthakur, Gautam: 9 articles (01/2022 - 01/2011)
8.	Kantarjian, Hagop: 9 articles (01/2020 - 05/2004)
9.	Konopleva, Marina: 8 articles (01/2022 - 04/2006)
10.	Perl, Alexander E: 8 articles (01/2022 - 01/2018)

Related Diseases

1.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 08/01/2020 - "Acute myeloid leukemia (AML) harboring Fms-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutation is associated with shorter remission and higher relapse risk. " 10/27/2010 - "Molecular characterization of the FMS-like tyrosine kinase 3 receptor (FLT3) in cytogenetically normal acute myeloid leukemia (AML) has recently been incorporated into clinical guidelines based on correlations between FLT3 internal tandem duplications (FLT3-ITD) and decreased disease-free and overall survival. " 10/01/2011 - "The aim of this study was to analyze the FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) allelic ratios (AR), number of ITD, ITD length and positions of ITD insertions in de novo acute myeloid leukemia (AML) patients with FLT3-ITD positive, and the relationship between mutant level and therapeutic efficacy. " 01/01/2021 - "Given the controversial roles of FMS-like tyrosine kinase 3 inhibitors (FLT3i) in various treatment stages of acute myeloid leukemia (AML), this study was designed to assess this problem and further explored which FLT3i worked more effectively. " 09/01/2016 - "The purpose of the study was to assess the effect of the internal tandem duplication in FMS-like tyrosine kinase 3 (FLT3-ITD) on the outcome in pediatric acute myeloid leukemia (AML) patients. "
2.	Leukemia 02/01/2018 - "Several studies have shown that internal tandem duplication (ITD) of FMS-like tyrosine kinase 3 (FLT3) can result in the failure of leukemia treatment and contribute to a poor prognosis. " 03/06/2014 - "We found that IDH2(R140Q) can cooperate with overexpression of HoxA9 and Meis1a and with mutations in FMS-like tyrosine kinase 3 (FLT3) to drive acute leukemia in vivo. " 01/01/2014 - "Another such possible target in pediatric acute leukemia is FMS-like tyrosine kinase 3 (FLT3). " 09/01/2011 - "The FMS-like tyrosine kinase 3 (FLT3) is highly expressed in acute leukemias. " 03/01/2010 - "Gene expression profiling experiments identified putative downstream MN1 targets, of which FMS-like tyrosine kinase 3 (FLT3) and CD34 were upregulated in both MN1-overexpressing murine leukemias and in pediatric acute leukemias with high MN1 levels. "
3.	Neoplasms (Cancer) 01/01/2023 - "Fms-like tyrosine kinase 3 (FLT3) is frequently mutated in haematological malignancies. " 01/01/2022 - "FMS-like tyrosine kinase 3 (FLT3) is known to be expressed in AML cancer cells. " 01/10/2017 - "We investigated the patients with solid cancers harboring Fms-like tyrosine kinase 3 (FLT3) amplification using targeted sequencing of tumor tissue specimen and FISH assay. " 12/01/2011 - "FMS-like tyrosine kinase 3 (FLT3) is critical for normal haematopoiesis and have been reported to be expressed in the majority of acute myeloid and lymphoid malignancies. " 04/15/2015 - "An improved understanding of how the signaling pathways [e.g., Fms-like tyrosine kinase 3 (Flt3), PI3K, and signal transducer and activator of transcription (Stat)] are dysregulated by these mutations in Cbl has helped to identify potential targets for therapy of myeloid neoplasms. "
4.	Chromosome Aberrations (Chromosome Abnormalities) 04/01/2020 - "Cytogenetic and molecular analyzes revealed chromosomal abnormalities (trisomy 8), PML-RARA gene fusion, and fms-like tyrosine kinase 3 (FLT3) gene mutation. " 05/21/2009 - "Here, we analyzed the impact of associated cytogenetic abnormalities or bad-prognosis fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) in 53 patients with CEBPA(+) de novo AML treated in the Acute Leukemia French Association trials. " 12/01/2022 - "Internal tandem duplications of the Fms-like tyrosine kinase 3 gene (FLT3-ITD) and additional chromosomal abnormalities (ACA) are prognostic factors in patients with acute promyelocytic leukemia (APL). " 07/01/2017 - "In addition, this SNP site is affinitive to the well-known molecular markers of AML, including Fms-like tyrosine kinase 3 and DNA methyltransferase 3A, as well as extramedullary lesions, periphery leukocyte numbers, remission and cytogenetic abnormalities of patients with AML. " 08/31/2021 - "Acute myeloid leukemia (AML) with fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) relapses with new chromosome abnormalities following chemotherapy, implicating genomic instability. "
5.	Thrombocytopenia (Thrombopenia) 08/01/2015 - "Pacritinib, a JAK2 and FMS-like tyrosine kinase 3 (FLT3) inhibitor, has shown promising results in early phase trials with limited myelotoxicity and clinical responses that are comparable with those seen with ruxolitinib, even in patients with severe thrombocytopenia. "

Related Drugs and Biologics

1.	Sorafenib (BAY 43-9006)
2.	Tyrosine Kinase Inhibitors
3.	Phosphotransferases (Kinase)
4.	gilteritinib
5.	Proteins (Proteins, Gene)
6.	midostaurin
7.	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
8.	venetoclax
9.	11- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaene
10.	ruxolitinib

Related Therapies and Procedures

1.	Therapeutics
2.	Hematopoietic Stem Cell Transplantation
3.	Drug Therapy (Chemotherapy)
4.	Induction Chemotherapy
5.	Cell Transplantation